This review explores the usage of GLP-1 receptor agonists as combination therapy with metformin and as monotherapy for patients with PCOS, and the subsequent metabolic and hormonal effects of the pharmacological therapy, such as improved lipid panels and reduced hyperandrogenism. This evidence concerns the gene GLP1R and polycystic ovary syndrome.